{"prompt": "['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', '9.3.1.4 Pharmacokinetics parameters', 'Observed SAR407899 concentrations will be reported in the clinical study report. A population', 'pharmacokinetic analysis may be conducted and will be reported in a separated report.', '9.3.2 Pharmacogenetic assessment', '9.3.2.1 Drug metabolizing enzymes DNA sample', 'Not applicable.', '9.3.2.2 Optional stored DNA sample', 'For those patients who signed the optional pharmacogenetic informed consent form, a blood', 'sample will be collected at the study visit as specified in the study flow chart and this sample will', 'be stored for up to 15 years after completion of the final study report of the main clinical trial.', 'This sample may be used to determine a possible relationship between genes and response to', 'treatment with SAR407899, how the body processes SAR407899, and possible side effects to', 'SAR407899. Genes that may be studied include those related to ROCK pathway and/or', 'endothelial dysfunction. This blood sample will be transferred to a site that will, on behalf of', 'Sanofi, extract DNA from the sample and that is managed by Covance.', 'This blood sample, and the DNA that is extracted from it, will be assigned a second number, a', 'genetic ID (deidentification code) that is different from the patient ID. This \"double coding\" is', \"performed to separate a subject's medical information and DNA data.\", 'The clinical study data (coded by subject ID) will be stored in the clinical data management', 'system (CDMS), which is a distinct database in a separate environment from the database', 'containing the pharmacogenetic data (coded by genetic ID). The key linking subject ID and', 'genetic ID will be maintained by a third party, under appropriate access control. The matching of', 'clinical data and pharmacogenetic data, for the purpose of data analysis, will be possible only by', 'using this key, which will be under strict access control. All data will be reported only in coded', 'form in order to maintain confidentiality.', 'The DNA will be stored for up to 15 years from the completion of the clinical study report.', 'Special procedures for storage and shipping of pharmacogenetic samples are described in a', 'separate laboratory manual and in Appendix B.', 'Property of the Sanofi Group - strictly confidential', 'Page 57', '(electronic 4.0)']['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', '9.4.1 Sampling / handling procedures', 'Table 1 - Summary of sampling/handling procedures for', 'Sample volume', '10 mL blood', 'Matrix', 'Serum', 'Anticoagulant', 'None', 'Handling procedures', 'See laboratory manual', 'Aliquot split', '4 aliquots with 1 mL serum for the first three aliquots, at each timepoint', 'Storage conditions', '-20\u00b0C', 'Shipment conditions', 'In dry ice', 'Table 2 - Summary of sampling/handling procedures for', 'Sample volume', '10 mL blood', 'Matrix', 'Serum', 'Anticoagulant', 'None', 'Handling procedures', 'See laboratory manual', 'Aliquot split', '4 aliquots with 1 mL serum for the first three aliquots, at each timepoint', 'Storage conditions', '-20\u00b0C', 'Shipment conditions', 'In dry ice', 'Special procedures for collection, storage and shipping of blood/plasma/serum will be described', 'in a separate laboratory manual.', '9.4.2 Biomarker assay methods', 'The methods are still under development. Methods will be described in a separate laboratory', 'manual.', '9.5', 'FUTURE USE OF SAMPLES FOR BIOMARKER SAMPLES', 'Table 3 - Summary of sampling/handling procedures for future use of samples', 'Sample volume', '4 mL blood', 'Matrix', 'Serum', 'Anticoagulant', 'None', 'Handling procedures', 'See laboratory manual', 'Aliquot split', '8 aliquot of 0.250 mL serum at each timepoint', 'Storage conditions', '-20\u00b0C', 'Shipment conditions', 'In dry ice', 'Property of the Sanofi Group - strictly confidential', 'Page 58', '(electronic 4.0)']\n\n###\n\n", "completion": "END"}